Unicycive Therapeutics, Inc. (UNCY) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US90466Y2028
Unicycive Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -29.52 m USD |
| EBIT | -27.50 m USD |
| Net income | -26.56 m USD |
| Diluted EPS – continuing operations | -1.67 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
More stocks
- SPSoft Inc. (443670.KQ)
- Shinhung (004080.KS)
- AEWIN Technologies Co.Ltd. (3564.TWO)
- Patria Bank SA (PBK.RO)
- Pharmosa Biopharm Inc. (6875.TWO)
- Chin Hsin Environ Engineering Co., Ltd. (6951.TW)
- QUALITAS SEMICONDUCTOR CO. LTD. (432720.KQ)
- GEORGE RISK INDUSTRIES, INC. (RSKIA)
- G2Power Co. Ltd. (388050.KQ)
- Karex Berhad (5247.KL)
- Ticketplus Ltd. (TP)
- We & Win Development Co Ltd (2537.TW)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.